Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
